6 TECH OUTLOOKDecember 2017Copyright © 2017 ValleyMedia Inc. All rights reserved. Reproduction in whole or part of any text, photography or illustrations without written permission from the publisher is prohibited. The publisher assumes no responsibility for unsolicited manuscripts, photographs or illustrations. Views and opinions expressed in this publication are not necessarily those of the magazine and accordingly, no liability is assumed by the publisher thereof.DECEMBER, 2017Mailing AddressValleyMedia Inc.44790 S. Grimmer Blvd Suite 202, Fremont, CA 94538T:510 230 0395, F:510-894-8405 DECEMBER, 2017, Vol 03 - 09 Published by ValleyMedia Inc. To subscribe to Pharma Tech OutlookVisit www.pharmatechoutlook.com Editor-in-ChiefStacey SmithEditorial StaffSalesVisualizerAsher BlakeS NityaAaron Pierce Arijit Sarkar Ava GarciaJenna Vegas Joshua ParkerJustin SmithGENOMICS SPECIALRichard Watson richard@pharmatechoutlook.comEditorialStacey Smith Editor-in-ChiefExciting advances in genomics technologies have leapfrogged unraveling of the human genome, the knowledge of which is set to bring about the transformative impact on health and wellbeing. The burgeoning cost of healthcare coupled with the inevitable need to deliver precision medicine, has been among the key drivers in mankind's relentless pursuit to decode the human genome sequence. The individual genetic blueprint holds the key to a person's susceptibility to a particular disease, drug resistance or effectiveness of medication amongst a plethora of factors to target personalized therapies and improve health conditions. Remarkable advances in genomics technologies in conjunction with groundbreaking research have been instrumental in creating pathways that are set to discover more cures and radically change healthcare delivery. As genome sequencing cost is becoming economically viable, remarkable advances in next-gen genomic technologies are proving to be the building block for better health. The disruptive technologies that impact pharmacogenomics, or the direct-to-consumer genomics or wearable data collection devices that today are at the heart of the medical Internet of Things are producing humongous amount of complex genomic data. This data need to be analyzed and translated into actionable clinical insights for precise prognosis and effective therapies. In tandem with this, developments in big data analysis and storage, and cloud-based solutions that decipher the data trove are advancing precision medicine. From Google's DeepVariant to solutions that are targeted at creating powerful drugs that take into consideration the finer variants from the mountains of genomic data, artificial intelligence boards the technology cart. Though past nascency, newer technologies continue to unfold with the radical gene editing techniques such as CRISPR-Cas9 impacting industries as varied as precision nutrition, pharmaceuticals, energy, and agriculture. For instance, research and trials are underway for T-cell-based cancer immunotherapies bringing to fore CRISPR's prowess in modifying genes and also treating rare genetic diseases. However, challenges could pose if CRISPR wrongly modifies an unintended gene, for which the scientific community's persistent research in tow with the evolutionary process of technology continues towards its goal of safety and precision.The affordable genome sequencing has in fact created a breeding ground for cutting-edge research and solutions. These are aimed at incisively interpreting the genomic data to fuel onward a wider portfolio of promising endeavors that fast-track the proposition of direct-to-consumer tests, and vastly improve genomic data security.The Transformative ForceTECH OUTLOOKTECH OUTLOOK*Some of the Insights are based on the interviews with respective CIOs and CXOs to our editorial staffT: 510-230-0395
< Page 5 | Page 7 >